DOCSLIB.ORG

2020 ANNUAL REPORT Transformative Realizing the Promise of Precision Medicines to Help Patients with Cancer Lead Better, Longer Lives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 ANNUAL REPORT Transformative Realizing the Promise of Precision Medicines to Help Patients with Cancer Lead Better, Longer Lives 2020 ANNUAL REPORT Transformative Realizing the promise of precision medicines to help patients with cancer lead better, longer lives SIGNIFICANT MARKET POTENTIAL TO TREAT LEVERAGING NEW OPPORTUNITY DEVASTATING DISEASE ADVANCES Novel menin inhibitor, Breakthrough Therapy Next-generation FTI KO-539, with potential Designation from FDA directed at new biology to treat 35% or more for tipifarnib in HNSCC and larger oncology of AML indications MULTIPLE EXPANSION ESTABLISHED STRONG CAPITAL OPPORTUNITIES LEADERSHIP TEAM POSITION Preparing to move into Proven oncology drug $633.3 million in cash, larger populations, development and cash equivalents and combinations and commercialization investments provide earlier lines of therapy expertise runway into 2024 To Our Shareholders This past year has been a truly transformative one for Kura Oncology. Despite the unique challenges we faced in 2020, we came together during the COVID-19 pandemic to adapt, evolve and grow, while remaining focused on our mission to realize the promise of precision medicines to help patients with cancer lead better, longer lives. Here are several highlights: Great Companies Are Built by Great People Despite the challenges of the past year, our organization has nearly doubled in size as we have added key functions. Our leadership team, hiring managers and human resource professionals have done a terrific job recruiting, onboarding, and integrating our newest colleagues virtually as we enlisted them in our mission to improve the lives “We focused our of patients. business around two major pillars, I am particularly pleased that, in August 2020, we recruited Stephen our emerging menin Dale, M.D., a globally recognized leader in drug development as our inhibitor, KO-539, Chief Medical Officer. Stephen joined us from Kyowa Kirin, where he and our late-stage served as SVP and Global Head of Medical Science. Previously, he farnesyl transferase was Global Clinical Vice President and Clinical Head of Oncology at inhibitor, tipifarnib. The results have been AstraZeneca, where among his many accomplishments, he oversaw the truly remarkable, and development of Tagrisso® (osimertinib) for metastatic EGFR-T790M we have positioned mutation-positive non-small cell lung cancer. our programs for continued Optimizing Our Business to Maximize Value for Shareholders advancement in the year ahead.” In early 2020, our leadership conducted an analysis with the goal of creating the greatest value for patients and shareholders, while Troy E. Wilson, Ph.D., J.D. balancing investment, risk and execution. As a result, we focused President & Chief our business and our efforts around two major pillars – our menin Executive Officer inhibitor, KO-539, in AML and our late-stage farnesyl transferase inhibitor, tipifarnib, in HNSCC. The results have been truly remarkable, and we have positioned our programs for continued advancement in the year ahead. KURA ONCOLOGY 2020 ANNUAL REPORT 1 KO-539 Demonstrates Highly Encouraging Preliminary Clinical Data in AML In December 2020, we presented the first clinical data from KOMET-001, our ongoing Phase 1/2 clinical trial of our menin inhibitor, KO-539, at the American Society of Hematology Annual Meeting. These data were highlighted by activity in an all-comer population of patients with relapsed or refractory acute myeloid leukemia (AML), and they support a potentially best-in-class profile both as a monotherapy and in combination. Now we look forward to obtaining a larger clinical dataset as we move into genetically enriched Phase 1b expansion cohorts, including NPM1 mutant AML and KMT2A rearranged relapsed/refractory AML patients. “The preliminary Breakthrough Therapy Designation for Tipifarnib in HRAS Mutant clinical data for Head and Neck Cancer KO-539 suggest it has the potential to be Earlier this year, our farnesyl transferase inhibitor, tipifarnib, received effective for multiple Breakthrough Therapy Designation from the FDA for the treatment genetically defined of patients with recurrent or metastatic HRAS mutant head and neck subgroups of acute squamous cell carcinoma (HNSCC). We appreciate the agency’s myeloid leukemia, affirmation of the potential for tipifarnib to treat this devastating where prognosis disease, and we look forward to working closely with them to bring this remains poor.” therapy to patients as soon as possible. Eunice Wang, M.D. Roswell Park Publication of Data from Our RUN-HN Study in Journal of Comprehensive Cancer Clinical Oncology Center We recently announced the publication of results from our Phase 2 RUN-HN trial of tipifarnib showing an objective response rate (ORR) of 55% with a median progression-free survival (PFS) of 5.6 months and median overall survival (OS) of 15.4 months in recurrent/ metastatic HRAS mutant HNSCC. The results formed the basis of tipifarnib’s Breakthrough Therapy Designation and support the AIM- HN registration-directed in patients with recurrent or metastatic HRAS mutant HNSCC, which is currently recruiting at more than 100 sites around the globe. 2 KURA ONCOLOGY 2020 ANNUAL REPORT New Approaches to Address Larger Patient Populations and Pursue Earlier Lines of Therapy As we continue to advance tipifarnib as a monotherapy in HNSCC, we are leveraging new advances and insights to expand its use in combination with other oncology therapeutics. Specifically, we have prioritized the combination of tipifarnib and an inhibition of the PI3Kα proto-oncogene in patients with HNSCC. We believe this combination has the potential to treat between 20-50% of HNSCC patients, a devastating disease for which there are no FDA approved small molecule targeted therapies, and we look forward to initiating this trial later this year. Strengthened Balance Sheet Along with executing against our ambitious R&D goals, we took the “We are encouraged opportunity last year to strengthen Kura’s balance sheet. I am pleased by the compelling to say that, with more than $600 million in cash, we have runway into at efficacy and safety least 2024 and the resources we need to reach critical value-inflection profile of tipifarnib in points for our programs. patients with recurrent or metastatic HRAS Well Positioned to Advance Our Drug Candidates in the Year Ahead mutant head and neck squamous cell On behalf of Kura’s leadership and board of directors, I would like carcinoma, a disease of to thank the patients in our clinical studies, our employees for their high unmet need.” willingness to adapt in unusual circumstances with courage and positivity, and our shareholders for your continued encouragement and Alan Ho, M.D., Ph.D. support as we navigated the storm of 2020. We remain committed to Memorial Sloan Kettering Cancer Center realizing the promise of precision medicines for the treatment of cancer, and I look forward to updating you on our progress in the year ahead. Sincerely, Troy E. Wilson, Ph.D., J.D. President & Chief Executive Officer KURA ONCOLOGY 2020 ANNUAL REPORT 3 Drug Candidate Pipeline Registration Program Preclinical Phase 1 Phase 2 Directed Acute Myeloid Leukemia (AML) KO-539 Menin Inhibitor • Enrollment in Phase 1 expansion cohorts expected to begin in mid-2021 HRASm Head and Neck Squamous Cell Carcinoma (HNSCC) Tipifarnib • Enrollment in AIM-HN registration-directed trial ongoing Farnesyl Transferase Inhibitor PI3Kɲ / HRAS dependent HNSCC • Initiation of PI3Kɲ inhibitor combination study expected in 2H 2021 Next-Generation Solid tumors Farnesyl Transferase Inhibitor • Nomination of development candidate expected in mid-2021 Relapsed/Refractory AML is a Challenging Disease “We are in a stronger Associated with Poor Outcomes financial position than ever before, with more NPM1-Mutant AML KMT2A(MLL)-Rearranged AML than $600 million in cash at the end of Estimated 6,000 new cases Estimated 1,000-2,000 new 2020, which we believe in the U.S. per year1 cases in the U.S. per year1 provides us with (~30% of AML) ( 5-10% of AML) sufficient resources to Known co-mutations confer NCCN guidelines denote advance our programs worse prognosis2 and represent that MLL-r confers 3 through multiple value- rational combination approaches poor prognosis inflection points.” Marc Grasso, M.D. Tipifarnib Has the Potential to be the First Small Chief Financial Officer Molecule Targeted Therapy for HNSCC Patients and Chief Business Officer Globally, ~885,000 people Outcomes with currently develop head and neck cancer available therapies (including annually and ~450,000 die of I-O therapy) are poor6 4 HNSCC each year OS First line: 10-15 mo; Second line: 5-8 mo 60,000+ cases of HNSCC per PFS year in the U.S.5 First line: 3-5 mo; Second line: 2-3 mo ORR First line: 20-36%; Second line: 13-16% 1 SEER statistics for AML in the US, accessed April 2020 2 Döhner et al. Blood. 2017 Jan 26;129(4):424-447 3 NCCN. AML Guidelines (version 3.2020). Accessed May 2020 4 Bray et al. CA Cancer J Clin. 2018;68(6):394-424 5 Cramer et al. Nat Rev Clin Oncol. 2019 Nov;16(11):669-683 | ACS Cancer Facts and Figures 2020 6 N Engl J Med. 2008 Sep 11;359(11):1116-27 | Keytruda & Opdivo package inserts | J Clin Oncol. 2007 Jun 1;25(16):2171-7 | J Clin Oncol. 2012 30:15_suppl, 5574-5574 4 KURA ONCOLOGY 2020 ANNUAL REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ց ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR տ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD
Load more

Recommended publications
  • Stock Price Effects of Breakthrough Therapy Designation
    NEWS & ANALYSIS SUPPLEMENTARY INFORMATION BIOBUSINESS BRIEFS In format as provided by the authors Stock price effects of breakthrough therapy designation David Hoffmann, Shane Van Dalsem and Frank S. David NATURE REVIEWS | D RU G D IS COVERY Supplementary Box 1 | Methods and data 1. Methods 1a. Sample definition and data collection Event data collection The website Friends of Cancer Research (http://www.focr.com/) lists all publicly available Breakthrough Therapy Designations (BTD), which were downloaded with a cut-off on 06/30/18. For partnered products, we treated each partner as if it had independently received the BTD, and thus generated an entry for each co-developing company. For each BTD, we identified the original press release and excluded companies that did not disclose the exact BTD announcement date. Further, we excluded companies that are not publicly traded on a US stock exchange, and those that had incomplete stock price data in the event period (as of 08/24/18). We also excluded BTDs that coincided with major corporate press releases (e.g., quarterly results or clinical trial news). In cases where the same company announced several BTDs on the same date, we retained only one for analysis. This yielded 146 BTDs (102 commercial, 44 pre-commercial). Subsequently, we identified three outliers and excluded them from the final CAAR analysis (see later section). 1 Stock price collection The historical closing stock prices (unadjusted) for the range of -111 days to +90 days around the disclosure of the BTD events were downloaded from https://finance.yahoo.com/. Historical stock prices from delisted companies were downloaded from https://amigobulls.com or https://barchart.com.
    [Show full text]
  • Merck & Co., Inc
    As filed with the Securities and Exchange Commission on February 25, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 _________________________________ FORM 10-K (MARK ONE) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File No. 1-6571 _________________________________ Merck & Co., Inc. 2000 Galloping Hill Road Kenilworth New Jersey 07033 (908) 740-4000 New Jersey 22-1918501 (State or other jurisdiction of incorporation) (I.R.S Employer Identification No.) Securities Registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock ($0.50 par value) MRK New York Stock Exchange 1.125% Notes due 2021 MRK/21 New York Stock Exchange 0.500% Notes due 2024 MRK 24 New York Stock Exchange 1.875% Notes due 2026 MRK/26 New York Stock Exchange 2.500% Notes due 2034 MRK/34 New York Stock Exchange 1.375% Notes due 2036 MRK 36A New York Stock Exchange Number of shares of Common Stock ($0.50 par value) outstanding as of January 31, 2021: 2,530,315,668. Aggregate market value of Common Stock ($0.50 par value) held by non-affiliates on June 30, 2020 based on closing price on June 30, 2020: $195,461,000,000. Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • Oregon Drug Use Review / Pharmacy & Therapeutics Committee
    © Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 | Fax 503-947-1119 Oregon Drug Use Review / Pharmacy & Therapeutics Committee Thursday, July 26, 2018 1:00 - 5:00 PM HP Conference Room 4070 27th Ct. SE Salem, OR 97302 MEETING AGENDA NOTE: Any agenda items discussed by the DUR/P&T Committee may result in changes to utilization control recommendations to the OHA. Timing, sequence and inclusion of agenda items presented to the Committee may change at the discretion of the OHA, P&T Committee and staff. The DUR/P&T Committee functions as the Rules Advisory Committee to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9). I. CALL TO ORDER 1:00 PM A. Roll Call & Introductions R. Citron (OSU) B. Conflict of Interest Declaration R. Citron (OSU) C. Approval of Agenda and Minutes T. Klein (Chair) D. Department Update T. Douglass (OHA) E. Legislative Update T. Douglass (OHA) F. Mental Health Clinical Advisory Group Discussion K. Shirley (MHCAG) 1:40 PM II. CONSENT AGENDA TOPICS T. Klein (Chair) A. P&T Methods B. CMS and State Annual Reports C. Quarterly Utilization Reports 1. Public Comment III. DUR ACTIVITIES 1:45 PM A. ProDUR Report R. Holsapple (DXC) B. RetroDUR Report D. Engen (OSU) C. Oregon State Drug Reviews K. Sentena (OSU) 1. A Review of Implications of FDA Expedited Approval Pathways, Including the Breakthrough Therapy Designation IV.
    [Show full text]
  • Jeff Allen, Ph.D. Executive Director, Friends of Cancer Research FDA Programs for Expediting Drug Review & Development
    Jeff Allen, Ph.D. Executive Director, Friends of Cancer Research FDA Programs for Expediting Drug Review & Development Jeff Allen, PhD Executive Director, Friends of Cancer Research Accelerating the Pace of Innovation Washington, DC-based Think Tank & Advocacy Organization A unique model to create a path to better drug development and approval through scientific, regulatory, and legislative Policy Science solutions. Develops groundbreaking partnerships: • Federal Agencies (FDA, NIH, NCI) • Academic Research Centers • Professional Societies Advocacy • Industry • Advocacy Organizations Approved NMEs in Oncology 2003-2010 FDA vs EMA Courtesy of the American Association of Cancer Research 2011 Cancer Progress Report FDA Programs for Expediting Drug Review & Development The FDA expedites the review of drugs treating serious conditions with the potential to provide significant improvements in safety or effectiveness over existing therapies: • Priority Review • Fast Track • Accelerated Approval • Breakthrough Therapy Designation Priority Review In 1992, the Prescription Drug User Fee Act set up specific goal times for review New Drug Applications (NDA) Priority Review cuts the time in which the FDA aims to take action on a drug’s application from ten months to six months. Requirements: • To be considered for Priority Review, a drug must address a serious condition and the drug must demonstrate, through clinical trial data or other scientifically valid information, the potential to provide a significant improvement in safety or effectiveness over existing treatments. When to Submit a Request: • Because Priority Review only impacts the marketing application review, which takes place late in the FDA approval process, drug sponsors generally submit requests either alongside or as a post-submission addition to a Biologics License Application (BLA) or New Drug Application (NDA).
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Q4 2018 Media Release
    Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland https://www.novartis.com FINANCIAL RESULTS • RÉSULTATS FINANCIERS • FINANZERGEBNISSE Novartis delivered strong sales growth with core margin expansion, built leading advanced therapy platforms and focused the company in 2018 Full year net sales up 5% (cc1, +6% USD) driven by strong performance of growth drivers: o Pharmaceuticals BU grew 7% (cc) driven by Cosentyx USD 2.8 billion (+36% cc) and Entresto USD 1.0 billion (+102% cc) o Oncology BU grew 9% (cc) driven by AAA2 (USD 0.4 billion) including Lutathera, Promacta/Revolade USD 1.2 billion (+35% cc) and Tafinlar + Mekinist USD 1.2 billion (+31% cc) Full year core1 operating income grew 8% mainly driven by higher sales and gross margin expansion Net income was USD 12.6 billion (+64%) including a USD 5.7 billion net gain from the divestment of OTC JV. Operating income declined 5% mainly due to M&A transactions and restructurings Free cash flow1 grew 12% to USD 11.7 billion driven by strong operating cash flows Focused the company with transformational deals during 2018: o Consumer healthcare JV stake divested to GSK for USD 13.0 billion o Announced proposal to spin-off Alcon Division3; on track for H1 2019 o Sandoz began transformation with reshaping the portfolio4, geographic focus and a leaner cost structure Built leading advanced therapy platforms: o Gene therapy – Acquired AveXis and in-licensed Luxturna o Radioligand therapy – Acquired AAA and Endocyte o Cell therapy – Expanding Kymriah global
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Regulatory Incentives for Innovation
    REGULATORY INCENTIVES FOR INNOVATION: THE FDA’S BREAKTHROUGH THERAPY DESIGNATION Amitabh Chandra1 Jennifer Kao2 Kathleen L. Miller3 Ariel D. Stern4 Abstract In approving new medical products, regulators confront a tradeoff between speeding a new product to market and collecting additional information about its quality. Alternatively, with the right allocation of resources, this tradeoff function may be “shifted outward,” thereby allowing important products to come to market more quickly without compromising quality evaluation. We study the FDA’s Breakthrough Therapy Designation (BTD), a novel policy tool that was created to accelerate the clinical development and regulatory approval processes for developers of high-value therapies by increasing feedback and communication with regulators during later phases of drug development. Using algorithmic matching models, we assess the impact of the BTD program on measures of (1) time-to-market and (2) post-approval drug safety. We find that the BTD program shortened late-stage clinical development times by 24 percent. We do not find evidence of a difference in the ex post safety profile of drugs with (vs. without) the BTD. In exploring mechanisms, we find support for reduced BTD trial design com- plexity, but not for trial size as driving these findings. The results suggest that targeted policy tools can shorten R&D periods without compromising the quality of new products. * The authors are grateful to seminar participants at the Allied Social Science Associations meeting, the Amer- ican Society of Health Economists Annual Conference, the Bates-White Life Sciences Symposium, the Harvard- MIT Center for Regulatory Science, the Munich Summer Institute, NABE Tech Conference, the NBER Produc- tivity Seminar, the Spreestadt-Forum on Health Care, and the University of San Francisco for valuable comments.
    [Show full text]
  • Rxoutlook® 4Th Quarter 2020
    ® RxOutlook 4th Quarter 2020 optum.com/optumrx a RxOutlook 4th Quarter 2020 While COVID-19 vaccines draw most attention, multiple “firsts” are expected from the pipeline in 1Q:2021 Great attention is being given to pipeline drugs that are being rapidly developed for the treatment or prevention of SARS- CoV-19 (COVID-19) infection, particularly two vaccines that are likely to receive emergency use authorization (EUA) from the Food and Drug Administration (FDA) in the near future. Earlier this year, FDA issued a Guidance for Industry that indicated the FDA expected any vaccine for COVID-19 to have at least 50% efficacy in preventing COVID-19. In November, two manufacturers, Pfizer and Moderna, released top-line results from interim analyses of their investigational COVID-19 vaccines. Pfizer stated their vaccine, BNT162b2 had demonstrated > 90% efficacy. Several days later, Moderna stated their vaccine, mRNA-1273, had demonstrated 94% efficacy. Many unknowns still exist, such as the durability of response, vaccine performance in vulnerable sub-populations, safety, and tolerability in the short and long term. Considering the first U.S. case of COVID-19 was detected less than 12 months ago, the fact that two vaccines have far exceeded the FDA’s guidance and are poised to earn EUA clearance, is remarkable. If the final data indicates a positive risk vs. benefit profile and supports final FDA clearance, there may be lessons from this accelerated development timeline that could be applied to the larger drug development pipeline in the future. Meanwhile, drug development in other areas continues. In this edition of RxOutlook, we highlight 12 key pipeline drugs with potential to launch by the end of the first quarter of 2021.
    [Show full text]
  • The Breakthrough Therapy Designation Implications and Strategic Business Considerations
    The Breakthrough Therapy Designation Implications and Strategic Business Considerations The breakthrough therapy designation has generated substantial interest since its creation one year ago, as this new pathway represents the most comprehensive set of clinical development benefits available for a pipeline agent. However, the breakthrough therapy pathway may also lead to potential commercial downsides and regulatory risk. Most notably, the limited dataset from the breakthrough clinical program may be insufficient to garner favorable pricing and reimbursement, particularly in Europe. In addition, the abridged clinical trials may not be considered satisfactory for regulatory approval in ex-U.S. markets. Taken together with several other commercial considerations, it is critical for manufacturers to develop a comprehensive understanding of these advantages and disadvantages prior to pursuing the breakthrough therapy pathway. A Novel Pathway Breaks quickly gain access to highly promising agents. To date, this designation has been Through The FDA granted 27 times for a variety of oncologic and non-oncologic indications (Appendix In late 2012, the breakthrough therapy Table 1). designation joined the ranks of fast track, priority review, and accelerated approval as The breakthrough therapy designation is a pathway to expedite clinical development intended for agents that have demonstrated of new agents. This pathway was formed as substantial benefit over the existing standard a result of the Food and Drug Administration of care for serious or life threatening conditions Safety and Innovation Act (FDASIA) and was with high unmet need. The designation may largely borne out of pressure from patient be based on initial clinical data or potentially advocacy groups and cancer societies to more even preclinical research.
    [Show full text]
  • Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration
    Allergan Exercises Option to Acquire Compound from Aptinyx Discovery Platform Under Ongoing Research Collaboration May 22, 2018 EVANSTON, IL – May 22, 2018 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today announced Allergan plc (NYSE: AGN) has exercised its option to acquire drug candidate AGN-241751, an oral small- molecule N-methyl-D-aspartate (NMDA) receptor modulator. Aptinyx discovered AGN-241751 utilizing its proprietary chemistry platform and the compound was selected for further development by Allergan under its ongoing research collaboration with Aptinyx. Allergan was granted option rights to a limited number of small molecules from the Aptinyx discovery platform under a research collaboration initiated in conjunction with its 2015 acquisition of Naurex, the predecessor company from which Aptinyx and its platform were spun out. Through that transaction, Allergan also acquired rapastinel, an intravenously administered NMDA receptor modulating tetrapeptide. Subsequently, rapastinel received Breakthrough Therapy designation from the U.S. Food and Drug Administration and Allergan is currently evaluating the compound in Phase 3 studies in major depressive disorder (MDD). “Through our productive research collaboration with Aptinyx and parallel development of rapastinel, we have gained important insights into NMDA receptor modulation as a potential therapeutic approach for depression,” said C. David Nicholson, Ph.D., chief R&D officer at Allergan.
    [Show full text]
  • To Breakthrough Medicines
    Accelerating Breakthrough Molecules… … to Breakthrough Medicines Karl Graham-Siegenthaler - F. Hoffmann-La Roche Ltd. Overview • “The Problem” • US Response to The Problem – Existing Procedures –BTD – BTD experience and learnings • EU Response to The Problem – Existing Procedures –PRIME •Intro • Experience to date • Areas to address 2 “THE PROBLEM” The Medicines Access Problem… …Too long & too expensive Pre Regulatory Drug Clinical Clinical Trials Discovery Review Testing Phase 1 Phase 2 Phase 3 5,000 250 5 1 PhV 10,000 Compounds Therapies Therapy Compounds Monitoring EMA Filing EMA HTA Approval HTA 28 member States 28 Pre-Clinical Research Pre-Clinical EMA Approval for Sale Approval EMA Closed & Open Innovation Open & Closed Number of Patients/Subjects Negotiation for Reimbursement Negotiation 20-100 100-500 1000-5000 3 – 6 Years 6 – 7 Years 2 – 5 Years Total Cost: € 1.5 Billion Shifting Landscape of Drug Development What is expected to change in the future? Transition from… To… • Magic moment • Life-span management • RCT only • Toolkit for evidence generation • Prediction • Monitoring • Big populations • Small populations • Focus on licensing • Focus on patient access • Regulators only • Regulators, HTAs, Payers • Open utilization • Outcome-based reimbursement 5 REGULATORY PATHWAYS: US TOOLS FOR ACCELERATING DEVELOPMENT US: Accelerated Approval • Allows the earlier approval of a product based on a surrogate endpoint, if the product: – (1) is for a serious or life threatening disease or condition, and – (2) the product has an effect,
    [Show full text]